FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

BACKGROUND: Fifty percent of patients with muscle–invasive bladder cancer (MI-BC) die from their disease and current chemotherapy treatment only marginally increases survival. Novel therapies targeting receptor tyrosine kinases or activated oncogenes may improve outcome. Hence, it is necessary to st...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kompier, Lucie C., Lurkin, Irene, van der Aa, Madelon N. M., van Rhijn, Bas W. G., van der Kwast, Theo H., Zwarthoff, Ellen C.
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2010
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2972209/
https://ncbi.nlm.nih.gov/pubmed/21072204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0013821
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires